Biotech · Private company · Seattle, WA, US
Nephrodi Therapeutics, Inc.
Track this companyFree. Adds Nephrodi Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards2
- Novel AMPK activator for treatment of congenital X-linked nephrogenic diabetes insipidus in pediatric patientsFiscal year 2026 · $998.6KNIH RePORTER 5R44DK127798-03 · fetched Nov 12, 2026
- Novel AMPK activator for treatment of congenital X-linked nephrogenic diabetes insipidus in pediatric patientsFiscal year 2025 · $1.1MNIH RePORTER 2R44DK127798-02 · fetched Nov 12, 2026